A phase II study of the proportion of criteria for The OncoGuide NCC Oncopanel System for the specimen of unresectable pancreatic cancer obtained by TopGain for EUS-guided fine-needle biopsy
Not Applicable
- Conditions
- Pancreatic cancer
- Registration Number
- JPRN-UMIN000043038
- Lead Sponsor
- ational Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
Not provided
Exclusion Criteria
1)The physician determines that the patient's enrollment in the study is inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of criteria for the NCC Oncopanel for the specimen obtained by EUS-guided fine-needle biopsy
- Secondary Outcome Measures
Name Time Method 1)Tumor cellularity and tissue area 2)The proportion of criteria for the FoundationOne 3)Tumor cellularity and tissue area by the nCounter system 4)The true proportion of criteria for the NCC Oncopanel and FoundationOne 5)Accuracy, sensitivity, specificity, technical success rate and complication rate (bleeding and pancreatitis) 6)A comparison of the proportion of criteria for the NCC Oncopanel between primary and metastatic lesion 7)Type of genetic mutation 8)The proportion of patients who actually received gene therapy 9)A comparison of OS and PFS between patients who actually received gene therapy and not received